CLINICAL_TRIALS ClinicalTrials.gov record update

Allogeneic Natural Killer T-Cells Expressing CD19 Specific Chimeric Antigen Receptor and Interleukin-15 in Relapsed or Refractory B-Cell Malignancies 2

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05487651
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:09.833116+00:00
Published At: 2023-05-18T00:00:00+00:00
Record Updated At: 2023-05-18
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["NHL, Relapsed, Adult", "B-cell Lymphoma", "B-cell Leukemia", "DLBCL - Diffuse Large B Cell Lymphoma", "ALL, Adult B Cell", "ALL, Childhood", "CLL/SLL"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-05-18"
protocolSection.identificationModule.nctId: "NCT05487651"
protocolSection.identificationModule.officialTitle: "Allogeneic Natural Killer T-Cells Expressing CD19 Specific Chimeric Antigen Receptor and Interleukin-15 in Relapsed or Refractory B-Cell Malignancies 2"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.